Cargando…

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sartore-Bianchi, Andrea, Pietrantonio, Filippo, Lonardi, Sara, Mussolin, Benedetta, Rua, Francesco, Crisafulli, Giovanni, Bartolini, Alice, Fenocchio, Elisabetta, Amatu, Alessio, Manca, Paolo, Bergamo, Francesca, Tosi, Federica, Mauri, Gianluca, Ambrosini, Margherita, Daniel, Francesca, Torri, Valter, Vanzulli, Angelo, Regge, Daniele, Cappello, Giovanni, Marchiò, Caterina, Berrino, Enrico, Sapino, Anna, Marsoni, Silvia, Siena, Salvatore, Bardelli, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386661/ https://www.ncbi.nlm.nih.gov/pubmed/35915157 http://dx.doi.org/10.1038/s41591-022-01886-0

Ejemplares similares

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
por: Giannini, Valentina, et al.
Publicado: (2022)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
por: Raimondi, A., et al.
Publicado: (2021)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases
por: Rizzetto, Francesco, et al.
Publicado: (2020)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Early‐onset colorectal cancer in young individuals
por: Mauri, Gianluca, et al.
Publicado: (2018)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

The chronos principle
por: Christodoulou, D M
Publicado: (1974)

Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer
por: Yokokawa, Hideyuki, et al.
Publicado: (2020)

Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors
por: Berrino, Enrico, et al.
Publicado: (2022)

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
por: Mauri, Gianluca, et al.
Publicado: (2021)

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
por: Siravegna, Giulia, et al.
Publicado: (2017)

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
por: Amodio, Vito, et al.
Publicado: (2023)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Les tactiques de Chronos
por: Klein, Etienne
Publicado: (2009)

Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients
por: Berrino, Enrico, et al.
Publicado: (2021)

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
por: Koukakis, Reija, et al.
Publicado: (2016)

Chronos: Stress Makes the Clock Tick
por: Robinson, Richard
Publicado: (2014)

Social dynamics modeling of chrono-nutrition
por: Di Stefano, Alessandro, et al.
Publicado: (2019)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
por: Borelli, Beatrice, et al.
Publicado: (2018)

Feasibility of Comparative Health Research Outcome of Novel Surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study
por: Day, Emily, et al.
Publicado: (2021)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
por: Russo, Mariangela, et al.
Publicado: (2018)

Tempo: il sogno di uccidere Chrónos
por: Tonelli, Guido
Publicado: (2021)

Chrono-Nutrition: Circadian Rhythm and Personalized Nutrition
por: Franzago, Marica, et al.
Publicado: (2023)

Editorial: The present and future of chrono-nutrition studies
por: Tahara, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_691tb1r07tenvtvve63dautj4m